Literature DB >> 19840778

Increased sensitivity to kainic acid in a genetic model of reduced NMDA receptor function.

Gary E Duncan1, Ken Inada, Beverly H Koller, Sheryl S Moy.   

Abstract

The pathophysiology of schizophrenia may involve reduced NMDA receptor function and experimental models of NMDA receptor hypofunction have proven useful for characterizing neurobiological abnormalities potentially relevant to schizophrenia. The present study assessed behavioral responses and induction of Fos after administration of kainic acid to wild type mice (NR1(+/+)) and mice with genetically reduced NMDA receptor expression (NR1(neo/neo)). At a dose of 20 mg/kg, kainic acid induced lethal seizures in 100% of the NR1(neo/neo) mice tested but produced no lethal seizures in the wild type mice. The NR1(neo/neo) mice also exhibited enhanced behavioral responses to kainic acid at a dose of 15 mg/kg but no lethal seizures were produced by this dose. A greater induction of Fos was observed in neocortical and limbic cortical regions of the NR1(neo/neo) compared to NR1(+/+) mice after administration of 15 mg/kg kainic acid. In contrast, there were no differences between the genotypes in kainic acid induced Fos in the amygdala, hippocampus, lateral septum, and nucleus accumbens. In order to determine if altered behavioral phenotypes of the NR1(neo/neo) mice could be related to increased sensitivity of kainate receptors to endogenous glutamate, effects of the highly selective kainate antagonist LY382884 were examined. The kainate antagonist reduced the exaggerated acoustic startle responses, deficits in prepulse inhibition of acoustic startle, and motor hyperactivity in the NR1(neo/neo) mice. These findings suggest that selective kainate receptor antagonists could be novel therapeutic candidates for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840778      PMCID: PMC2787847          DOI: 10.1016/j.brainres.2009.10.023

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  39 in total

1.  Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function.

Authors:  Sheryl S Moy; Antonio Perez; Beverly H Koller; Gary E Duncan
Journal:  Brain Res       Date:  2006-04-25       Impact factor: 3.252

2.  Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function.

Authors:  Gary E Duncan; Sheryl S Moy; Jeffery A Lieberman; Beverly H Koller
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

3.  Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics.

Authors:  L J Garey; K A Von Bussmann; S R Hirsch
Journal:  Exp Brain Res       Date:  2006-02-28       Impact factor: 1.972

4.  Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders.

Authors:  Monica Beneyto; Lars V Kristiansen; Akinwunmi Oni-Orisan; Robert E McCullumsmith; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2007-02-14       Impact factor: 7.853

5.  Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.

Authors:  Gary E Duncan; Sheryl S Moy; Jeffrey A Lieberman; Beverly H Koller
Journal:  Pharmacol Biochem Behav       Date:  2006-11-13       Impact factor: 3.533

6.  Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder.

Authors:  Tsutomu Sakai; Akihiko Oshima; Yusuke Nozaki; Itsuro Ida; Chie Haga; Haruhiko Akiyama; Yoichi Nakazato; Masahiko Mikuni
Journal:  Neuropathology       Date:  2007-12-05       Impact factor: 1.906

7.  Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder.

Authors:  Tsung-Ung W Woo; Kevin Shrestha; Christopher Amstrong; Martin M Minns; John P Walsh; Francine M Benes
Journal:  Schizophr Res       Date:  2007-08-14       Impact factor: 4.939

Review 8.  Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review.

Authors:  L Watis; S H Chen; H C Chua; S A Chong; K Sim
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

9.  Anxiolytic-like effects through a GLUK5 kainate receptor mechanism.

Authors:  Andrew Alt; Brianne Weiss; Paul L Ornstein; Scott D Gleason; David Bleakman; Robert E Stratford; Jeffrey M Witkin
Journal:  Neuropharmacology       Date:  2007-03-02       Impact factor: 5.250

10.  Assessment of NMDA receptor activation in vivo by Fos induction after challenge with the direct NMDA agonist (tetrazol-5-yl)glycine: effects of clozapine and haloperidol.

Authors:  K Inada; J S Farrington; S S Moy; B H Koller; G E Duncan
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

View more
  9 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 2.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 3.  The relevance of individual genetic background and its role in animal models of epilepsy.

Authors:  P Elyse Schauwecker
Journal:  Epilepsy Res       Date:  2011-10-15       Impact factor: 3.045

4.  Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function.

Authors:  Gary E Duncan; Beverly H Koller; Sheryl S Moy
Journal:  Brain Res       Date:  2012-01-20       Impact factor: 3.252

5.  Synaptic drive at developing synapses: transient upregulation of kainate receptors.

Authors:  Brigitte van Zundert; Jiang-Ping Zhao; Martha Constantine-Paton
Journal:  Dev Neurobiol       Date:  2010-09-15       Impact factor: 3.964

6.  Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders.

Authors:  Hendrik Wesseling; Paul C Guest; Chi-Ming Lee; Erik Hf Wong; Hassan Rahmoune; Sabine Bahn
Journal:  Mol Autism       Date:  2014-07-04       Impact factor: 7.509

Review 7.  Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy-Mitochondria, Calcium Dynamics and Reactive Oxygen Species.

Authors:  Stjepana Kovac; Albena T Dinkova Kostova; Alexander M Herrmann; Nico Melzer; Sven G Meuth; Ali Gorji
Journal:  Int J Mol Sci       Date:  2017-09-08       Impact factor: 5.923

8.  Effect of developmental NMDAR antagonism with CGP 39551 on aspartame-induced hypothalamic and adrenal gene expression.

Authors:  Kate S Collison; Angela Inglis; Sherin Shibin; Soad Saleh; Bernard Andres; Rosario Ubungen; Jennifer Thiam; Princess Mata; Futwan A Al-Mohanna
Journal:  PLoS One       Date:  2018-03-21       Impact factor: 3.240

9.  Effect of NMDA on proliferation and apoptosis in hippocampal neural stem cells treated with MK-801.

Authors:  Juan Ding; Yu Shao; Hui-Hui Zhou; Quan-Rui Ma; Yi-Wei Zhang; Yin-Xiu Ding; Yu-Qing He; Juan Liu
Journal:  Exp Ther Med       Date:  2018-06-22       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.